ABP - Abpro Holdings, Inc.

0.2618
0.002   0.688%

Share volume: 126,806
Last Updated: 04-10-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.06%

PREVIOUS CLOSE
CHG
CHG%
$0.26
0.00
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-14.22%
1 Month
-46.41%
3 Months
-60.63%
6 Months
-60.63%
1 Year
-60.63%
2 Year
-60.63%
Key data
Stock price
$0.26
P/E Ratio 
N/A
DAY RANGE
$0.26 - $0.28
EPS 
N/A
52 WEEK RANGE
$0.23 - $0.73
52 WEEK CHANGE
-$60.63
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$243,958
AVERAGE 30 VOLUME 
$124,712
Company detail
CEO: Jin Wook Suk and Ian Chan
Region: US
Website: abpro.com
Employees: 15
IPO year: 2024
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company's product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer. It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema. Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.

Recent news

Abpro Statement on the Departure of Former CEO Ian Chan

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, “As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his serv

Read more